MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Seres Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42−0.04 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $23.59M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
-11910.1%−11644.8 pts over 5 years
Net margin
721.9%+990.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | -52.0% | -52.7% | – | |
| Net income | +4088.2% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -54.2% | -141.0% | 19.6% | |
| Return on assets | -37.4% | -37.5% | 4.1% | |
| Current ratio | 6.51 | 5.79 | 2.56 | |
| Debt to equity | – | 0.14 | – | |
| Net debt to EBITDA | – | 1.12× | – | |
| Interest coverage | – | -30.1× | – | |
| Capex to revenue | 98.7% | 1.8% | 31.9% | |
| Diluted shares | 2M | 4M | 9M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Seres Therapeutics generated $502.58M from operations and spent $27.99M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$502.58M
Used
$27.99M
Capital expenditure$27.99M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin721.9%
×Asset turnover0.01×
×Equity multiplier4.79×
=Return on equity, FY202519.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 721.9% | 0.01× | 4.79× | 19.6% |
| FY2022 | -3509.5% | 0.02× | 4.95× | -351.6% |
| FY2021 | -45.2% | 0.42× | 2.28× | -42.8% |
| FY2020 | -268.3% | 0.14× | 3.76× | -141.0% |
| FY2019 | -203.7% | 0.27× | -2.62× | 145.9% |
| FY2018 | -350.0% | 0.18× | 24.50× | -1563.8% |
| FY2017 | -278.4% | 0.14× | 2.39× | -92.5% |
| FY2016 | -420.7% | 0.09× | 1.45× | -54.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$5.70M
- Cash generatingOperating cash flow above zero$1.12M
- Return on assets improvedROA up on the prior year0.0% → 4.1%
- Earnings backed by cashOperating cash flow above net income$1.12M vs $5.70M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose0.94 → 2.56
- No dilutionShare count did not rise8M → 9M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.01